Bank of America Corp DE trimmed its holdings in shares of Genmab A/S (NASDAQ:GMAB – Get Rating) by 1.3% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 850,120 shares of the company's stock after selling 11,121 shares during the period. Bank of America Corp DE owned 0.13% of Genmab A/S worth $30,757,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also recently added to or reduced their stakes in the business. Captrust Financial Advisors boosted its position in Genmab A/S by 62.0% in the 1st quarter. Captrust Financial Advisors now owns 2,658 shares of the company's stock valued at $96,000 after buying an additional 1,017 shares during the last quarter. Sentinel Trust Co. LBA purchased a new position in Genmab A/S in the 4th quarter valued at about $219,000. Seven Eight Capital LP purchased a new position in Genmab A/S in the 1st quarter valued at about $215,000. SG Americas Securities LLC boosted its position in Genmab A/S by 9.3% in the 1st quarter. SG Americas Securities LLC now owns 6,050 shares of the company's stock valued at $219,000 after buying an additional 513 shares during the last quarter. Finally, Wrapmanager Inc. boosted its position in Genmab A/S by 30.7% in the 1st quarter. Wrapmanager Inc. now owns 6,757 shares of the company's stock valued at $244,000 after buying an additional 1,589 shares during the last quarter. 5.51% of the stock is owned by hedge funds and other institutional investors.
Get Genmab A/S alerts:Wall Street Analyst Weigh In
A number of research firms have weighed in on GMAB. BMO Capital Markets began coverage on shares of Genmab A/S in a research report on Thursday, June 23rd. They issued a "market perform" rating and a $34.73 price objective for the company. TheStreet upgraded shares of Genmab A/S from a "c+" rating to a "b" rating in a research note on Wednesday, August 31st. HC Wainwright upped their target price on shares of Genmab A/S from $49.00 to $51.00 and gave the company a "buy" rating in a research note on Monday, August 22nd. Morgan Stanley upped their target price on shares of Genmab A/S from $29.00 to $31.00 and gave the company an "underweight" rating in a research note on Monday, August 15th. Finally, SVB Leerink upped their target price on shares of Genmab A/S from $30.00 to $31.00 and gave the company a "market perform" rating in a research note on Thursday, August 11th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Hold" and an average price target of $547.62.
Genmab A/S Stock Up 0.6 %
GMAB opened at $32.13 on Friday. The firm has a market cap of $21.15 billion, a price-to-earnings ratio of 35.70, a price-to-earnings-growth ratio of 1.19 and a beta of 0.85. Genmab A/S has a fifty-two week low of $26.19 and a fifty-two week high of $47.28. The company's 50-day moving average price is $35.35 and its 200 day moving average price is $33.92.Genmab A/S (NASDAQ:GMAB – Get Rating) last released its quarterly earnings data on Wednesday, August 10th. The company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.20. The firm had revenue of $452.86 million for the quarter, compared to analyst estimates of $435.40 million. Genmab A/S had a net margin of 38.42% and a return on equity of 17.12%. Research analysts anticipate that Genmab A/S will post 1.02 earnings per share for the current year.
Genmab A/S Company Profile
(Get Rating)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Featured Stories
- Get a free copy of the StockNews.com research report on Genmab A/S (GMAB)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- Thor Industries Hammers Out A Bottom
- Declining Profits Challenge the CarMax Value Proposition
Want to see what other hedge funds are holding GMAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genmab A/S (NASDAQ:GMAB – Get Rating).
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.